What's Happening?
A recent study has highlighted the potential benefits of Solriamfetol, a drug marketed under the brand name Sunosi, for early-morning workers suffering from fatigue. Conducted by Dr. Charles A. Czeisler and his team at Mass General Brigham, the study focused
on individuals who start work between 3 a.m. and 7 a.m., a group often overlooked in sleep disorder research. These workers typically experience fatigue due to waking up at a time when their circadian rhythms are naturally at a low point. The study involved 78 participants who were given either Solriamfetol or a placebo over four weeks. Results showed that those taking Solriamfetol stayed awake an average of 12.5 minutes longer during alertness tests compared to a 3.1-minute improvement in the placebo group. This significant difference suggests that Solriamfetol could help early-morning workers maintain alertness throughout their shifts.
Why It's Important?
The findings of this study are significant as they provide a potential solution for the millions of early-morning workers who struggle with fatigue, which can lead to increased risks of cardiovascular disease, road accidents, and chronic fatigue. By improving wakefulness, Solriamfetol could enhance job performance, safety, and overall quality of life for these workers. The drug's ability to maintain alertness without disrupting afternoon sleep offers an advantage over other treatments like modafinil. This research could lead to broader acceptance and use of Solriamfetol for shift work disorder, providing a medically backed option for a condition that affects a substantial portion of the workforce.
What's Next?
Following the promising results of this study, further research is planned to test Solriamfetol on overnight workers, which could lead to formal approval of the drug for shift work disorder. If successful, Solriamfetol would become the first medication specifically labeled for this condition. This development could prompt healthcare providers to consider Solriamfetol as a viable treatment option for early-morning workers, potentially influencing workplace policies and health recommendations. The study's publication in NEJM Evidence adds credibility to these findings, encouraging further exploration and potential regulatory approval.
